Arcus Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Number of shares of common stock · Common stock and additional paid-in capital · Accumulated deficit · Accumulatedothercomprehensive loss · Totalstockholders’ equity
Balance at December 31, 2022	72.9	$1,206			$(542)			$(7)			$657
Issuance of common stock in connection with our equity award programs	0.2	1			—			—			1
Stock-based compensation	—	19			—			—			19
Other comprehensive income	—	—			—			3			3
Net loss	—	—			(80)			—			(80)
Balance at March 31, 2023	73.1		1,226			(622)			(4)			600
Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' Equity)	1.0	20			—			—			20
Issuance of common stock in connection with our equity award programs	0.4	3			—			—			3
Stock-based compensation	—	18			—			—			18
Net loss	—	—			(75)			—			(75)
Balance at June 30, 2023	74.5		1,267			(697)			(4)			566
Issuance of common stock	0.2	5			—			—			5
Issuance of common stock in connection with our equity award programs	0.1	1			—			—			1
Stock-based compensation	—	18			—			—			18
Other comprehensive income	—	—			—			1			1
Net loss	—	—			(71)			—			(71)
Balance at September 30, 2023	74.8	$1,291			$(768)			$(3)			$520
Balance at December 31, 2023	75.5	$1,311			$(849)			$—			$462
Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' Equity)	15.2	228			—			—			228
Issuance of common stock in connection with our equity award programs	0.2	2			—			—			2
Stock-based compensation	—	20			—			—			20
Other comprehensive loss	—	—			—			(1)			(1)
Net loss	—	—			(4)			—			(4)
Balance at March 31, 2024	90.9		1,561			(853)			(1)			707
Issuance of common stock in connection with our equity award programs	0.4	1			—		—			1
Stock-based compensation	—	20			—		—			20
Net loss	—	—			(93)			—			(93)
Balance at June 30, 2024	91.3		1,582			(946)			(1)			635
Issuance of common stock in connection with our equity award programs	0.2	1			—			—			1
Stock-based compensation	—	19			—			—			19
Other comprehensive income	—	—		—		2		2
Net loss	—	—			(92)			—			(92)
Balance at September 30, 2024	91.5	$1,602			$(1,038)			$1			$565

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.